Portal de Periódicos da CAPES

Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes

2023; Multidisciplinary Digital Publishing Institute; Volume: 12; Issue: 12 Linguagem: Inglês

10.3390/jcm12123925

2077-0383

Almudena Castro Conde, Domingo Marzal Martín, Raquel Campuzano Ruiz, María Rosa Fernández Olmo, Carlos Morillas Ariño, Juan José Gómez‐Doblas, José Luis Górriz, Pilar Mazón‐Ramos, Xavier García–Moll, María José Soler Romeo, David León Jiménez, Vicente Arrarte, Juan Carlos Obaya, Carlos Escobar Cervantes, Juan José Gorgojo Martínez,

Pharmacology and Obesity Treatment

Type 2 diabetes (T2DM) is one of the main public health care problems worldwide. It is associated with a marked increased risk of developing atherosclerotic vascular disease, heart failure, chronic kidney disease and death. It is essential to act during the early phases of the disease, through the intensification of lifestyle changes and the prescription of those drugs that have been shown to reduce these complications, with the aim not only of achieving an adequate metabolic control, but also a comprehensive vascular risk control. In this consensus document, developed by the different specialists that treat these patients (endocrinologists, primary care physicians, internists, nephrologists and cardiologists), a more appropriate approach in the management of patients with T2DM or its complications is provided. A particular focus is given to the global control of cardiovascular risk factors, the inclusion of weight within the therapeutic objectives, the education of patients, the deprescription of those drugs without cardiovascular benefit, and the inclusion of GLP-1 receptor agonists and SGLT2 inhibitors as cardiovascular protective drugs, at the same level as statins, acetylsalicylic acid, or renin angiotensin system inhibitors.